Zacks Investment Research upgraded shares of Remedent (OTCMKTS:REMI) from a sell rating to a hold rating in a research note published on Wednesday, reports.

According to Zacks, “REMEDENT, INC., a publicly-traded company on the OTCBB, specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. With offices in California, Belgium and Singapore, Remedent distributes its products in more then thirty five countries. “

Shares of OTCMKTS REMI opened at $0.20 on Wednesday. Remedent has a 52 week low of $0.11 and a 52 week high of $0.26.

Remedent (OTCMKTS:REMI) last issued its quarterly earnings data on Thursday, February 14th. The company reported ($0.01) EPS for the quarter. The business had revenue of $0.42 million during the quarter. Remedent had a negative net margin of 38.10% and a negative return on equity of 20.64%. As a group, equities analysts expect that Remedent will post 0.01 EPS for the current year.

Remedent Company Profile

Remedent, Inc, through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping.

Featured Story: What is a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Remedent (REMI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Remedent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Remedent and related companies with's FREE daily email newsletter.